https://www.freethink.com/health/crispr-cure-for-hiv Skip to content Open the Main Navigation Menu Open the Main Navigation Menu Freethink Subscribe Open the Main Navigation Menu Open the Main Navigation Menu Freethink Primary Menu * About + #50658 (no title) + Careers + Contact Us + For Brands + Privacy Policy * Challenges * It's the news, reimagined. * Move the World * Skoll | Rethinking Possible * T-Minus Thank You * Video Library CRISPR cure for HIV now tested in 3 people Here what we know -- and what we don't. By Kristin Houser October 29, 2023 Fields CRISPR Medicine Share * Copy a link to the article entitled CRISPR cure for HIV now tested in 3 people * Share CRISPR cure for HIV now tested in 3 people on Twitter * Share CRISPR cure for HIV now tested in 3 people on Facebook An HIV infected cell Credit: NIAID By Kristin Houser October 29, 2023 California-based biotech company Excision BioTherapeutics has shared data from the first human clinical trial of a CRISPR cure for HIV -- and it's both encouraging and frustratingly light on details. The challenge: HIV is no longer the death sentence it once was, thanks largely to antiretroviral therapy (ART), daily medications that can decrease the amount of the virus in a person's blood to levels that are undetectable and untransmittable. ART doesn't cure HIV, though -- it just forces the virus to enter a dormant state, hiding its DNA in a person's immune cells. If the person with HIV stops taking their ART, the virus can become active again, potentially leading to new symptoms and even death. EBT-101 instructs a CRISPR system to hunt down the HIV hiding in a person's cells. CRISPR cure for HIV: Excision BioTherapeutics is one of several groups exploring the use of the gene-editing technology CRISPR to outright cure HIV, freeing people from a lifetime of ART. Their treatment, EBT-101, instructs a CRISPR system to hunt down the HIV hiding in a person's cells and make three cuts to the HIV genome. Those cuts are designed to break the genetic recipe for the virus and eliminate any possibility of it reemerging. What's new? After promising studies in mice and non-human primates with SIV -- the monkey version of HIV -- the Excision team launched a clinical trial of its CRISPR cure for HIV in 2022. On October 25, 2023, they shared the first data from the trial at the European Society for Gene & Cell Therapy's annual meeting in Brussels, Belgium -- but missing from the announcement was any data about whether the therapy worked. None of the patients experienced serious adverse effects from the CRISPR therapy. What we know: During the presentation, the Excision team announced that it had administered a single IV infusion of EBT-101 to three people with HIV. All three had undetectable levels of HIV prior to starting the study, thanks to ART. None of the patients experienced serious adverse effects from the CRISPR therapy, and the four mild adverse effects observed all resolved on their own. Four weeks after treatment, EBT-101 could be found in the blood of all three participants. The missing link: While the primary purpose of the trial is to test the safety and tolerability of the CRISPR therapy, the researchers also planned to have "all eligible participants" stop taking ART 12 weeks after receiving EBT-101 to see if their HIV rebounded. (The therapy would be restarted again if it did reemerge.) It's not clear what makes a trial participant eligible, but at least one of the patients received the CRISPR therapy more than a year ago. If they stopped taking their ART, Excision isn't ready to share whether the treatment prevented or delayed their HIV from returning. Excision promises to present more trial data in 2024. Looking ahead: In the next phase, Excision plans to administer a larger dose of EBT-101 to six more trial participants in the fourth quarter of 2023. This dose escalation was planned from the start of the study, so it doesn't indicate whether the smaller dose did or didn't work. As for when we'll find out whether a CRISPR cure for HIV is within our grasp, Excision promises to present more trial data in 2024. Whether or not any of these patients were cured, larger trials will be needed to get more definitive answers about the treatment's safety and efficacy. But EBT-101 is not the only lead in the hunt for a universal HIV cure -- we also have stem cell transplants, medications, and other CRISPR therapies showing promise against the elusive virus. We'd love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected]. Fields CRISPR Medicine Share * Copy a link to the article entitled CRISPR cure for HIV now tested in 3 people * Share CRISPR cure for HIV now tested in 3 people on Twitter * Share CRISPR cure for HIV now tested in 3 people on Facebook Related images showing the effect of the treatment on neuromuscular junctions Biology Blocking this one protein could strengthen muscles Stanford researchers have figured out how a therapy that blocks a single protein can reverse age-related muscle loss in mice. Kristin Houser A man is holding up a living pharmacy prototype, which looks like a small piece of plastic with lines on it Medicine "Living pharmacies" could mean you never forget to take your meds again The US government is funding the development of "living pharmacies," implants containing cells that release medications on demand. Kristin Houser A person using a syringe to inject something into a petri dish. CRISPR New "anti-CRISPR" discovered in viruses A new "anti-CRISPR" system could help us control gene-editing tech and battle antibiotic-resistant superbugs. Kristin Houser An electron micrograph of an HIV-1 virus particle (gold) connected to an infected T cell (green) Medicine "Hydrogel" drugs could suppress HIV with minimal treatments An injectable solution that self-assembles into a hydrogel to deliver 6 weeks of anti-ARV drugs could make managing HIV less of a burden. Sam Jarman A woman laying in the grass with her eyes closed. Healthcare What the science really says about vitamin D deficiency When is low vitamin D a potential concern? And when might you need to get your levels tested? Here's what the evidence says. Elina Hypponen Up Next a monkey in a lab A monkey that survived for 758 days with a kidney from a gene-edited pig is a major step forward for xenotransplantation research. Surgery Monkey lives with CRISPR'd pig kidney for over two years Kristin Houser Subscribe to Freethink for more great stories Notice: JavaScript is required for this content. Subscription Center Freethink Media Subscribe to Freethink Weekly At Freethink, we believe the daily news should inspire people to build a better world. While most media is fueled by toxic politics and negativity, we focus on solutions: the smartest people, the biggest ideas, and the most ground breaking technology shaping our future. Notice: JavaScript is required for this content. Info * About Freethink * Partner with Us * Careers Video * Video Library * Series * Playlists Series * Just Might Work * Challengers * Hard Reset * Catalysts Sections * Space * Cities * Transportation * Energy * Internet * Consumer Tech * Futurology * Robots & AI * Hard Tech * Health * AR & VR * Society Playlists * The Best in Bionics * We <3 Space * DIY Technology * Interviews That Might Change Your Mind * Subscribe to our Youtube Channel * View our Instagram feed * Visit our Facebook page * View our Twitter feed (c) 2023 Freethink Media Inc. All Rights Reserved. * Privacy Policy Close * Subscribe to our Youtube Channel * View our Instagram feed * Visit our Facebook page * View our Twitter feed Sections * Space * Cities * Transportation * Energy * Internet * Consumer Tech * Futurology * Robots & AI * Hard Tech * Health * AR & VR * Society Video * Hard Reset * Challengers * Just Might Work * Playlists * Video Library Freethink * About Freethink * Partner With Us * Careers * Privacy Policy Subscribe We focus on solutions: the smartest people, the biggest ideas, and the most ground breaking technology shaping our future. Subscribe Search for:[ ][Search] Close Advertisement